2011/08/01 by Jingyuan Sun, Hua Xiang, Lin Yang +1 · 1 citation
Medicine · Chemistry · #Hormonal Regulation and Hypertension #Urinary Bladder and Prostate Research #Prostate Cancer Treatment and Research #Finasteride #Dihydrotestosterone #Hyperplasia #Reductase #5 Alpha-Reductase Inhibitor #Medicine #Prostate #Enzyme #Pharmacology #Endocrinology #Androgen #Cancer research #Chemistry #Internal medicine #Biochemistry #Hormone #Cancer
paper · doi:10.2174/092986711796642517
openalex publication_date 2011/08/01 · openalex created_date 2016/06/24 · openalex updated_date 2026/07/31
Benign prostatic hyperplasia (BPH) is a kind of common noncancerous prostate gland enlargement with growing tendency in recent years. 5α-reductase is the key enzyme responsible for dihydrotestosterone biosynthesis and has been considered as an important target for designing inhibitors as potent therapeutic agents for BPH. Finasteride, the first steroidal 5α-reductase inhibitor, has been marketed worldwide as a drug for BPH. During these years, many other novel types of 5α-reductase inhibitors are being studied. This review summarizes recent advancement in steroidal 5α-reductase inhibitors. Keywords: 5α-Reductase, 5α-reductase inhibitors, benign prostatic hyperplasia, dihydrotestosterone, steroid, finasteride, azasteroid, 3-carboxylic acid, pregnane derivatives, natural products